Deutsche Biotech Innovativ AG

  • WKN: A0Z25L
  • ISIN: DE000A0Z25L1
  • Land: Deutschland

Nachricht vom 09.09.2015 | 10:46

Deutsche Biotech Innovativ AG: First Berlin starts coverage with EUR 67.90 price target

DGAP-News: Deutsche Biotech Innovativ AG / Key word(s): Research Update

2015-09-09 / 10:46


Deutsche Biotech Innovativ AG: First Berlin starts coverage with EUR 67.90 price target

Hennigsdorf, 9 September 2015 - With the publication of the first research report, First Berlin Equity Research GmbH is starting coverage of Deutsche Biotech Innovativ AG ("DBI"). First Berlin's initial assessment gives the company's share a 'buy' rating and sees the fair value of the share at EUR67.90.

As strengths of the company, First Berlin analyst Simon Scholes emphasises, inter alia, DBI's innovative development approach. As a starting point for the identification of new drug targets DBI uses the thorough analysis of the blood of diseased patients. Only afterwards a target-related drug is being developed. This differs strongly from the conventional approach, in which targets are identified in animals first, and by this raises the probability that a drug candidate proves to be efficacious in the human body at the end of the development process. First Berlin also takes a favourable view of the unique approach to treating sepsis with DBI's lead product, the drug Adrecizumab, and DBI's strategic patent portfolio, which protects DBI's sepsis drug development until at least 2032.

Pipeline with blockbuster potential
DBI's revenue potential particularly arises from the three current drug candidates that are in development in DBI's project companies. First Berlin's analyst sees the market potential of the sepsis drug Adrecizumab as being around EUR3.6 billion a year. The market potential of DB1RA, a drug for the prevention of breast cancer, is estimated at EUR1.7 billion a year and the drug AB2302 for the treatment of cancer could accordingly achieve revenues of EUR0.8 billion a year.

The complete research study is available on Deutsche Biotech Innovativ AG's website via the following link:

Share split executed as planned
Following the resolution by the annual general meeting on 23 July 2015 to issue bonus shares, the company's share capital now, after the measure is completed, is EUR894,600.00, divided into 894,600 no-par value bearer shares. Thus, the price target of First Berlin relates to the fair value after share split.

About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG ("DBI") is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. Its focus is on drugs for sepsis and cancer. The company's main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting in 2015.

The preclinical and clinical studies are mainly carried out by project companies in which DBI AG holds a stake. Currently, DBI AG holds 26% of AdrenoMed AG (Agent: Adrecizumab), 25% of Oncoprevent GmbH (Agent: DB1RA), 100% of AngioBiomed GmbH (Agent: AB2302) and 50% of My Life Diagnostics GmbH (Diagnostic agent for urinary tract infection).

DBI aims to further expand its drug pipeline and invest in the research and development of drugs that have high unique-selling-point potential.

Both members of DBI's Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialising in the identification of blood biomarkers for treating serious illnesses. It was sold in 2009 for around EUR330 million. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).

For more information, please contact:

Deutsche Biotech Innovativ AG
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811

Kirchhoff Consult AG
Ms. Anja Ben Lekahl
Tel.: +49 (0)40 609 186 55

2015-09-09 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

393387  2015-09-09 

IPO im Fokus


ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC im Fokus

Börsengang sdm SE: Attraktives Investment

Der Sicherheitsdienstleister sdm SE führt derzeit einen Börsengang am Primärmarkt der Börse Düsseldorf durch. Die Mittel des Börsengangs sollen die Wachstumsstrategie finanzieren und die Ertragskraft deutlich steigern. Im Rahmen unseres DCF-Bewertungsmodells haben wir einen fairen Unternehmenswert (Post Money) zum Ende des Geschäftsjahres 2022 in Höhe von 15,23 Mio. € bzw. 4,09 € je sdm-Aktie ermittelt. Unter einem Preis von 3,50 € pro Aktie sehen wir sdm als ein attraktives Investment und stufen die Aktie mit dem Rating „Kaufen“ ein.

News im Fokus

Continental passt Ausblick für das Geschäftsjahr 2021 an und veröffentlicht vorläufige Kennzahlen für das dritte Quartal 2021

22. Oktober 2021, 14:11

Aktueller Webcast


Pressekonferenz – Zwischenmitteilung 9M 2021 - Webcast

28. Oktober 2021

Aktuelle Research-Studie

Aves One AG

Original-Research: Aves One AG (von GBC AG): Halten

21. Oktober 2021